<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Inter Press ServiceHEALTH: Finance First in Today&#039;s Drug Testing</title>
	<atom:link href="https://www.ipsnews.net/2004/10/health-finance-first-in-todays-drug-testing/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.ipsnews.net/2004/10/health-finance-first-in-todays-drug-testing/</link>
	<description>News and Views from the Global South</description>
	<lastBuildDate>Sun, 22 Nov 2026 15:11:55 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>
		<item>
		<title>HEALTH: Finance First in Today&#8217;s Drug Testing</title>
		<link>https://www.ipsnews.net/2004/10/health-finance-first-in-todays-drug-testing/</link>
		<comments>https://www.ipsnews.net/2004/10/health-finance-first-in-todays-drug-testing/#respond</comments>
		<pubDate>Wed, 06 Oct 2004 07:05:00 +0000</pubDate>
		<dc:creator>IPS Correspondents</dc:creator>
				<category><![CDATA[Development & Aid]]></category>
		<category><![CDATA[Economy & Trade]]></category>
		<category><![CDATA[Global]]></category>
		<category><![CDATA[Global Geopolitics]]></category>
		<category><![CDATA[Headlines]]></category>
		<category><![CDATA[Health]]></category>

		<guid isPermaLink="false">http://ipsnews.net/?p=12504</guid>
		<description><![CDATA[Ritt Goldstein]]></description>
		
			<content:encoded><![CDATA[<p><font color="#999999"><p class="wp-caption-text">Ritt Goldstein</p></font></p><p>By IPS Correspondents<br />STOCKHOLM, Oct 6 2004 (IPS) </p><p>Even before giant drug maker Merck &#038; Co announced  Sep. 29 it was withdrawing its arthritis medication Vioxx from the market,  voices were rising against the world&#8217;s drug makers, also known as &#8216;Big  Pharma&#8217;.<br />
<span id="more-12504"></span><br />
The critics have accused manufacturers of corrupting the process through which new drugs are approved by, among other things, distorting crucial drug information; alternately intimidating and seducing vast segments of the healthcare community; and using &#8220;stealth marketing,&#8221; such as funding and influencing so-called educational opportunities for medical professionals.</p>
<p>They point to evidence suggesting these problems began evolving decades ago, bred by a shift in medicine&#8217;s focus from patient care to financial concern. Evidence indicates the global community is indeed paying a high price for its medicines.</p>
<p>Much of the problem appears to exist within the drug approval and testing process.</p>
<p>According to noted clinical psychologist Dr John Read, one of the Pacific&#8217;s leading authorities on psychiatric medications, author of &#8216;Models of Madness&#8217;, and director of clinical psychology at the University of Auckland, the pharmaceutical industry routinely suppresses the results of negative drug trials.</p>
<p>&#8220;You conduct study after study after study, until you find two that produce the required results. You submit those and bury the rest,&#8221; Read charged.<br />
<div id='related_articles'>
 <h1 class="section">Related IPS Articles</h1>
<ul>
<li><a href="http://ipsnews.net/2004/10/health-drug-industry-scandal-a-crisis" >HEALTH: Drug Industry Scandal a &apos;Crisis&apos;</a></li>
</ul></div><br />
When asked how such a process was possible, he suggested that people in the United States &#8220;ask the FDA (the Food and Drug Administration, the body that regulates medications), &#8216;how that can be&#8217;.&#8221;</p>
<p>A Sep. 10 article in the &#8216;Washington Post&#8217; reported: &#8220;More than two-thirds of all studies of antidepressant use among depressed children have failed to show the drugs are effective.&#8221;</p>
<p>Problems with new medications have become so egregious that in the May 1, 2002 issue of the &#8216;Journal of the American Medical Association&#8217; (JAMA), five physicians from Harvard Medical School emphatically urged, &#8220;clinicians should avoid using new drugs when older, similarly efficacious agents are available.&#8221;</p>
<p>Critics charge that the erupting scandal over drug testing and efficacy represents the most visible evidence of medicine&#8217;s long-time siege by an extreme &#8220;free-market&#8221; ideology.</p>
<p>Striking to what may be the heart of the issue, Joel Lexchin, a professor in the School of Health Policy and Management at Toronto&#8217;s York University, says, &#8220;the FDA is putting free-market values above public-safety.&#8221;</p>
<p>Lexchin, who consults for bodies such as the World Health Organisation (WHO), as well as the Canadian and Australian governments, widely blamed ideologues who &#8220;push a business agenda in public policy&#8221; for the development.</p>
<p>The idea that &#8220;the economic interests of the industry should take priority over the public health,&#8221; is not a phenomenon &#8220;unique to the FDA,&#8221; he added.</p>
<p>What has emerged is an increasingly close and symbiotic relationship between the drug industry, the medical community, the regulatory community and certain political elements, vast sums of money cementing the network together.</p>
<p>According to a Sep. 2 report by MSNBC, as drug company profits soared throughout the 1980s and 1990s, so did their political muscle. If Big Pharma &#8220;didn&#8217;t like something about the FDA &#8230; it could change it through direct pressure or through its friends in Congress,&#8221; charged Dr Marcia Angell, former editor-in-chief of the prestigious &#8216;New England Journal of Medicine&#8217; and a senior lecturer at Harvard Medical School.</p>
<p>A single drug can bring a firm billions of dollars in profit. MSNBC noted that in 2003, Big Pharma&#8217;s profits (as a percentage of their sales) were over three times higher than the median rate for Fortune 500 industries.</p>
<p>And while in the 20 years prior to 1980 the industry&#8217;s prescription drug sales had remained at a relatively flat rate, in the next 20 years they tripled. But that had nothing to do with the quality of the drugs the companies were selling, Angell argued.</p>
<p>Tracing the evolution of today&#8217;s crisis for IPS, noted British drug scientist and psychiatrist Dr David Healy, explained, &#8220;In the course of the last 30 years, the whole clinical trial process has become a process that the (pharmaceutical) industry has taken more and more control of,&#8221; he said.</p>
<p>Healy recalled that when people within the university system had previously run clinical trials for pharmaceutical companies, the trials would have taken place at &#8220;one or two hospitals,&#8221; and the researcher running them would have received all the data generated, and then written a report based upon it. But that changed.</p>
<p>He describes today&#8217;s trials as &#8220;multi-centred,&#8221; noting they &#8220;slipped out of the control of any one person within the university system. And the data &#8230; ends up going back to the pharmaceutical companies.&#8221;</p>
<p>With the trial data hidden from public knowledge, other changes have occurred, Healy continues. &#8220;What we&#8217;ve seen in the course of the last 10 or 15 years is that, increasingly, the pharmaceutical companies get big-name authors (physicians) to be the authors on clinical trials that the companies have written-up.&#8221;</p>
<p>&#8220;What&#8217;s actually happening here is that clinical trials are being ghost-written,&#8221; he argues.</p>
<p>With the raw data out of public view, physicians who allow their names to be used in this manner &#8220;really don&#8217;t have to worry if the way the stuff has been written up is a faithful representation of what the raw data looks like, or not,&#8221; says Healy.</p>
<p>And without any contrary facts available to question a study&#8217;s alleged findings, failed drug trials have been repeatedly painted as successes.</p>
<p>&#8220;They&#8217;ve (the pharmaceutical companies) published as positive trials, trials which everyone else &#8211; when they get to see the raw data &#8211; realise are not positive trials. That actually &#8230; it&#8217;s clear that the drug didn&#8217;t work, and that it had hazards,&#8221; Healy charged.</p>
<p>When contacted for this article, the Pharmaceutical Research And Manufacturers of America (PhRMA) said no one was immediately available for comment.</p>
<p>Asked to put a conservative number on the full spectrum of medicine-related deaths, deaths caused by &#8220;all of the things the drug companies should have made public but didn&#8217;t,&#8221; Lexchin estimates the number could well be &#8220;200,000 per year in the United States,&#8221; both in-hospital and out.</p>
<p>That translates to an estimated one million U.S. deaths over the last five years due to drug company and regulatory failures.</p>
<p>Other estimates and research support Lexchin&#8217;s figure.</p>
<p>A 1998 estimate from JAMA and also published in Britain&#8217;s noted medical journal, &#8216;The Lancet&#8217;, placed the number of U.S. deaths in excess of 100,000 yearly, but included only in-hospital fatalities. A 2002 JAMA article called fatal drug reactions &#8220;a leading cause of death.&#8221;</p>
<p>Both Lexchin and &#8216;The Lancet&#8217; noted that proportionate numbers were perishing throughout the West. The projected global death toll is vast.</p>
<p>In the United States, many of the current questions about pharmaceutical industry practices seem to date from 1980, critics seeing those practices as a product of the Bayh-Dole Act of that year.</p>
<p>With the passage of the act, the &#8220;firewall was removed&#8221; between U.S. researchers at federally funded universities and the business community, according to a paper presented at the U.S. military&#8217;s 14th Tri-Service Clinical Investigation Symposium in 2002.</p>
<p>The paper, by Vera Hassner Sharav, argues that along with a flood of biotechnology and pharmaceutical industry money &#8220;came corporate influence and control &#8230; business ethics swept aside the moral framework within which academia had functioned.&#8221;</p>
<p>Perceiving present problems, the paper noted &#8220;the absence of independent, third-party review has put the integrity of the process and the quality of the products in jeopardy.&#8221;</p>
<p>Read&#8217;s &#8216;Models of Madness&#8217; describes &#8220;a steady flow of alarming cases in recent years where inconvenient scientific findings have been suppressed or rewritten, and those responsible for them hounded off their campuses with their professional and personal reputations systematically trashed,&#8221; courtesy of pharmaceutical firms.</p>
<p>It also refers to &#8220;unbridled capitalism,&#8221; echoing Lexchin&#8217;s observation of a &#8220;neo-liberal, extreme free-market agenda.&#8221;</p>
<p>On Sep. 25, 2000, &#8216;USA Today&#8217; released a study of financial conflicts of interest within the FDA&#8217;s medical advisory committees &#8211; official groups where, &#8220;with few exceptions, the FDA follows the committees&#8217; advice.&#8221;</p>
<p>Still widely quoted, the &#8216;USA Today&#8217; report discovered that at the most important policy meetings, those on &#8220;broader issues,&#8221; 92 percent of those present had a financial conflict of interest, a financial stake in the very issues they were addressing.</p>
<p>It noted that while U.S. law &#8220;generally prohibits&#8221; those with such a conflict from serving in these positions, &#8220;the FDA has waived the restriction more than 800 times since 1998,&#8221; effectively leaving it meaningless.</p>
<p>Reflecting on the evolution of events, noted Canadian-American psychologist, educator and author Daniel Burston observed it has been established that &#8220;a consensus is only as good as the judgement of the individuals who comprise the &#8216;panel of experts&#8217; it&#8217;s based upon.&#8221;</p>
<p>&#8220;If the consensus is based upon the opinions of people whose judgement has been compromised &#8230; in some fashion, then it becomes worthless or worse,&#8221; added Burston in an interview.</p>
<p>According to Read, the pharmaceutical industry is &#8220;engaged in the deliberate seduction of the medical profession, country by country, worldwide.&#8221; &#8220;It is spending a fortune on influencing, hiring, and purchasing academic judgement to a point where &#8230; unbought medical opinion will be hard to find.&#8221;</p>
<p>Regarding psychiatric medications, Read argues (and this has been independently confirmed), there&#8217;s &#8220;an endless bombardment of the medical professions with false information masquerading as &#8216;educational information&#8217; .. carefully selected and screened information &#8230; leaving out the many, many studies that show these drugs are often dangerous and often ineffective.&#8221;</p>
<p>A considerable portion of the problem stems from the structure of the medical profession, he argues.</p>
<p>Read notes that it is &#8220;very hard&#8221; for medical professionals to obtain &#8220;neutral or independent training&#8221; after graduation, arguing that healthcare professionals are now &#8220;almost entirely dependent on drug company information for all of their post-graduate training for the 50 years that they practice.&#8221;</p>
<p>He calls the existing situation &#8220;an appalling state of affairs.&#8221;</p>
<p>On Sep. 28, AP reported that U.S. physicians &#8220;who receive drug company funding would be limited in what they could teach other physicians under new rules being proposed by accreditors.&#8221;</p>
<div id='related_articles'>
 <h1 class="section">Related Articles</h1>
<ul>
<li><a href="http://ipsnews.net/2004/10/health-drug-industry-scandal-a-crisis" >HEALTH: Drug Industry Scandal a &apos;Crisis&apos;</a></li>
</ul></div>		<p>Excerpt: </p>Ritt Goldstein]]></content:encoded>
			<wfw:commentRss>https://www.ipsnews.net/2004/10/health-finance-first-in-todays-drug-testing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
